Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers.

Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, Olesen J, Ashina M

Cephalalgia : an international journal of headache1 Aug 2006Cited by 77 (Europe PMC)

PMID16886936DOI10.1111/j.1468-2982.2006.01149.xPepBankPUB-16886936

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialSafety outcome
In healthy volunteers, headache was very mild (maximum score 2); five participants had headache during VIP infusion and one during placebo.
In plain wordsIn healthy volunteers, VIP infusion caused only a very mild headache: five people had one with VIP and one with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeadache during VIP infusion
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Measurements
Maximum headache score
2 0-10 scale
VIP
Source sentences
Summary
Five participants developed headache during VIP and one during placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
The headache was very mild with a maximum score of 2 and described as a pressing or throbbing sensation.
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693601
02HumanRandomized controlled trialMechanism
In healthy volunteers, VIP caused a significant drop in mean flow velocity in the middle cerebral artery during infusion compared with placebo.
In plain wordsIn healthy volunteers, VIP slowed blood flow in a main brain artery during the infusion, compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseMean flow velocity in the middle cerebral artery during infusion
Study
n = 12
Comparator
Placebo
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
a significant drop in V(meanMCA) was seen for VIP compared with placebo (P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693602
03HumanRandomized controlled trialMechanism
In healthy volunteers, the VIP effect on middle cerebral artery flow velocity waned quickly, with no difference from placebo between 30 and 120 minutes.
In plain wordsIn healthy volunteers, the VIP effect on brain artery blood flow faded quickly and did not differ from placebo after 30 minutes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeMean flow velocity in the middle cerebral artery, 30 to 120 min
Study
n = 12
Comparator
Placebo
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
but the effect quickly waned and no difference was found when comparing the time between 30 and 120 min.
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693603
04HumanRandomized controlled trialMechanism
In healthy volunteers, VIP caused no significant difference in the diameter of the middle cerebral artery during infusion.
In plain wordsIn healthy volunteers, VIP did not change the width of a main brain artery during infusion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeMiddle cerebral artery diameter
Study
n = 12
Comparator
Placebo
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
In addition, no significant difference in the diameter of the MCA could be found during the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693604
05HumanRandomized controlled trialMechanism
In healthy volunteers, regional cerebral blood flow did not differ significantly between VIP and placebo.
In plain wordsIn healthy volunteers, VIP did not change blood flow in the brain compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeRegional cerebral blood flow
Study
n = 12
Comparator
Placebo
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
No significant differences in rCBF (P = 0.10) were found between VIP and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693605
06HumanRandomized controlled trialMechanism
In healthy volunteers, VIP caused a marked dilation of the superficial temporal artery in the first 30 minutes of infusion.
In plain wordsIn healthy volunteers, VIP widened an artery in the temple during the first 30 minutes, compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseSuperficial temporal artery dilation, first 30 min
Study
n = 12
Comparator
Placebo
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
A marked dilation of the superficial temporal artery was seen (P = 0.04) after VIP in the first 30 min
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693606
07HumanRandomized controlled trialMechanism
In healthy volunteers, the VIP effect on superficial temporal artery dilation did not differ from placebo between 30 and 120 minutes.
In plain wordsIn healthy volunteers, the VIP effect on an artery in the temple was no longer different from placebo after 30 minutes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeSuperficial temporal artery dilation, 30 to 120 min
Study
n = 12
Comparator
Placebo
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
but no difference was found when comparing the time between 30 and 120 min.
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693607
08HumanRandomized controlled trialSafety outcome
In healthy volunteers, mean arterial blood pressure did not differ between VIP and placebo days.
In plain wordsIn healthy volunteers, VIP did not change blood pressure compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeMean arterial blood pressure
Study
n = 12
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
We found no difference in mean arterial blood pressure between VIP and placebo days
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693608
09HumanRandomized controlled trialSafety outcome
In healthy volunteers, heart rate increased significantly on the VIP day compared with the placebo day.
In plain wordsIn healthy volunteers, VIP raised the heart rate compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeart rate
Study
n = 12
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
the heart rate increased significantly on a VIP day compared with a placebo day (AUC(0-30 min), P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693609
10HumanRandomized controlled trialPharmacokinetics
In healthy volunteers, plasma VIP was significantly higher on the VIP day than on the placebo day.
In plain wordsIn healthy volunteers, VIP levels in blood were higher after the VIP infusion than after placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma VIP concentration
Study
n = 12
Comparator
Placebo
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
8 pmol/kg per min · infusion · 25 minAs given in this study (human).
Source sentences
Summary
Plasma VIP was significantly higher on a VIP day compared with placebo (AUC(0-80 min), P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
VIP (8 pmol/kg per min) or placebo (0.9% saline) was infused for 25 min into 12 healthy young volunteers in a crossover, double-blind design.
Report a problemFND-1688693610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.